Asimov vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mammalian Cell Engineering Platform for Biologics & Gene Therapy
Asimov develops software and AI tools for mammalian cell engineering to accelerate design and manufacturing of biologics and gene therapies; combines synthetic biology, biophysical simulation, and machine learning;
About
Asimov is a Boston-based biotechnology and computational biology company founded in 2017 by Alec Nielsen, Raja Srinivas, and Christopher Voigt. The company's mission is to apply software engineering principles to cell engineering — treating genetic circuits in mammalian cells the way software engineers treat code. Asimov builds computational tools and AI models that predict how genetic constructs will behave in mammalian cells, enabling researchers to design, simulate, and optimize biologics and gene therapy vectors before conducting expensive wet lab experiments.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.